Estados Unidos - inglés - NLM (National Library of Medicine)

apace packaging - enalapril maleate (unii: 9o25354epj) (enalapril - unii:69pn84io1a) - enalapril maleate 2.5 mg

Estados Unidos - inglés - NLM (National Library of Medicine)

cardinal health - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - enalapril maleate 5 mg

Estados Unidos - inglés - NLM (National Library of Medicine)

dispensing solutions, inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - enalapril maleate 20 mg

Estados Unidos - inglés - NLM (National Library of Medicine)

remedyrepack inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - enalapril maleate 20 mg - hypertension vasotec is indicated for the treatment of hypertension. vasotec is effective alone or in combination with other antihypertensive agents, especially thiazide- type diuretics. the blood pressure lowering effects of vasotec and thiazides are approximately additive. heart failure vasotec is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients vasotec improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). asymptomatic left ventricular dysfunction in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), vasotec decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see clinical pharmacology, heart failure, mortality trials for details and limitations of survi

Estados Unidos - inglés - NLM (National Library of Medicine)

proficient rx lp - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - enalapril maleate is indicated for the treatment of hypertension. enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trial

Estados Unidos - inglés - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - enalapril maleate is indicated for the treatment of hypertension. enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see error! hyperlink reference not valid. for details and limitations of survival trials). in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see error! hyperlink reference not valid. for details and limitations of survival trials). in using enalapril maleate cons

Estados Unidos - inglés - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - enalapril maleate is indicated for the treatment of hypertension. enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see error! hyperlink reference not valid. for details and limitations of survival trials). in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see error! hyperlink reference not valid. for details and limitations of survival trials). in using enalapril maleate cons

Estados Unidos - inglés - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - enalapril maleate is indicated for the treatment of hypertension. enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see error! hyperlink reference not valid. for details and limitations of survival trials). in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see error! hyperlink reference not valid. for details and limitations of survival trials). in using enalapril maleate cons

Estados Unidos - inglés - NLM (National Library of Medicine)

solco healthcare us, llc - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - enalapril maleate tablets are indicated for the treatment of hypertension. enalapril maleate tablets are effective alone or in combination with other antihypertensive agents, especially thiazidetype diuretics. the blood pressure lowering effects of enalapril maleate tablets and thiazides are approximately additive. enalapril maleate tablets are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate tablets improve symptoms, increase survival, and decrease the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate tablets decrease the rate of development of overt heart failure and decrease the incidence of hospitalization for heart failure (see clinical pharmacology, heart failure, mortality trials f

Australia - inglés - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - enalapril maleate, quantity: 5 mg - tablet, uncoated - excipient ingredients: sodium bicarbonate; magnesium stearate; lactose monohydrate; maize starch; pregelatinised maize starch - hypertension: renitec is indicated in the treatment of: - all grades of essential hypertension; - renovascular hypertension. congestive heart failure: renitec is indicated for the treatment of all degrees of symptomatic heart failure. in such patients, it is recommended that renitec be administered together with a diuretic. left ventricular dysfunction: all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35%, irrespective of the presence or severity of obvious symptoms of heart failure.